Finance, Grants, Deals

Argenx makes its New York debut

Belgium-based Argenx NV has made its debut on the Nasdaq over-the-counter market in the US, capping what has been nearly a decade of successful antibody discovery and development. On 17 May, it announced the pricing of an initial public offering (IPO) of its shares that was set to yield $100 million.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

Money for Italian biotech

A group of biotech entrepreneurs, led by a former executive at Novartis, has announced plans to raise €50 million for a fund that will invest in Italian life science. The fund is being managed by AurorA-TT, a technology transfer company set up in Milan earlier this year.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Italy

Celyad licenses technology to Novartis

Belgium-based Celyad SA, which used to go by the name of Cardio3 BioSciences SA, has secured a non-exclusive licensing agreement with Novartis giving the Swiss company rights to US patents for the production of allogeneic CAR T cells.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

Immunocore identifies new lead compound

The Oxford, UK oncology company Immunocore Ltd has identified a lead compound in its second discovery collaboration with GlaxoSmithKline Plc which is expected to have potential for treating triple negative breast cancers, oesophageal, gastric and ovarian cancers.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Takeda takes option on GammaDelta

Less than a year after its founding, GammaDelta Therapeutics Ltd has received an investment from Takeda Pharmaceutical Company Ltd, which sees promise in the UK company’s T cell platform as a source for new immunotherapies.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

AZ buys rights to preclinical respiratory asset

AstraZeneca Plc has taken steps to bolster its respiratory portfolio with a licensing deal for a preclinical drug candidate that is being developed for patients with moderate to severe asthma.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Offer for Germany’s leading generic producer

The management of Stada Arzneimittel AG, Germany’s leading generics producer, has accepted a €4.1 billion offer for the company from two private equity firms, Bain Capital Private Equity LP of Boston Massachusetts, US and Cinven Partners LLP of London, UK.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Germany

Nanobiotix raises €25.1 million in private placement

Nanobiotix SA, which is developing technology for enhancing radiotherapy treatments, has raised €25.1 million in a private share placement to finance its portfolio and the expected European market launch of its lead product NBTXR3.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

France

Symetis gains access to US market

Switzerland-based Symetis GmbH has made a major step onto the US medical device market after agreeing to be acquired by Boston Scientific Corp. The deal, announced on 30 March, consolidates the two companies’ technologies for treating valvular heart disease.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

Seed funding for Imperial College spin-out

Cardian Ltd, a new spin-out from Imperial College London, has received £1.5 million in seed funding to commercialise a device for monitoring patients with heart failure and help physicians manage their care. The device does not need batteries or a power line.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Syndicate content